Trastuzumab biosimilar - Mycenax Biotech

Drug Profile

Trastuzumab biosimilar - Mycenax Biotech

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mycenax Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 09 Aug 2017 Trastuzumab biosimilar - Mycenax Biotech is available for licensing as of 09 Aug 2017. http://www.mycenax.com.tw/en/goods.php?act=view&no=6
  • 09 Aug 2017 Early research in Breast cancer in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top